JPWO2022019945A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022019945A5 JPWO2022019945A5 JP2023504420A JP2023504420A JPWO2022019945A5 JP WO2022019945 A5 JPWO2022019945 A5 JP WO2022019945A5 JP 2023504420 A JP2023504420 A JP 2023504420A JP 2023504420 A JP2023504420 A JP 2023504420A JP WO2022019945 A5 JPWO2022019945 A5 JP WO2022019945A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- fusion protein
- composition
- cytokine
- cdrs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063054208P | 2020-07-20 | 2020-07-20 | |
| US63/054,208 | 2020-07-20 | ||
| PCT/US2020/062907 WO2022019945A1 (en) | 2020-07-20 | 2020-12-02 | Dual cytokine fusion proteins comprising il-10 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023534847A JP2023534847A (ja) | 2023-08-14 |
| JPWO2022019945A5 true JPWO2022019945A5 (https=) | 2023-12-11 |
| JP2023534847A5 JP2023534847A5 (https=) | 2023-12-11 |
Family
ID=79291996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023504420A Pending JP2023534847A (ja) | 2020-07-20 | 2020-12-02 | Ｉｌ－１０を含む二重サイトカイン融合タンパク質 |
Country Status (11)
| Country | Link |
|---|---|
| US (19) | US11292822B2 (https=) |
| EP (1) | EP4181957A4 (https=) |
| JP (1) | JP2023534847A (https=) |
| KR (1) | KR20230096959A (https=) |
| CN (1) | CN116322785A (https=) |
| AU (1) | AU2020459746A1 (https=) |
| BR (1) | BR112023001187A2 (https=) |
| CA (1) | CA3186753A1 (https=) |
| IL (1) | IL300062A (https=) |
| MX (1) | MX2023000948A (https=) |
| WO (1) | WO2022019945A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7641912B2 (ja) | 2019-04-19 | 2025-03-07 | シナーキン・ファーマ・ベスローテン・フエンノートシャップ | Ｉｌ１３を含む融合タンパク質 |
| CA3186753A1 (en) | 2020-07-20 | 2022-01-27 | John Mumm | Dual cytokine fusion proteins comprising il-10 |
| JP2024546999A (ja) * | 2021-12-16 | 2024-12-26 | デカ バイオサイエンシーズ， インコーポレイテッド | Ｉｌ－１０を含む二重サイトカイン融合物およびがんを処置するための養子細胞療法または二重特異性ｔ細胞エンゲージャー |
| CN118900697A (zh) * | 2022-02-22 | 2024-11-05 | 德卡生物科学公司 | 使用白细胞介素减轻双特异性t细胞接合器或嵌合抗原受体t细胞介导的细胞因子释放综合征的方法 |
| KR20250078792A (ko) * | 2023-11-24 | 2025-06-04 | 주식회사 메드팩토 | 피브로넥틴 엑스트라도메인 B (Extradomain B of Fibronectin, EDB-FN) 및 전환성장인자 베타(transforming growth factor β, TGFβ)에 특이적으로 결합하는 융합 단백질 및 이의 용도 |
| WO2025148750A1 (zh) * | 2024-01-08 | 2025-07-17 | 上药生物治疗（香港）有限公司 | 膜表达il-10及其用途 |
| CN119954974B (zh) * | 2025-04-09 | 2025-07-22 | 四川康德赛医疗科技有限公司 | 一种工程化巨噬细胞，其制备方法及抗纤维化的应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5989867A (en) | 1996-09-23 | 1999-11-23 | Knappe; Andrea | DNA encoding IL-10-like homologue; related reagents |
| JP4793971B2 (ja) * | 1999-08-09 | 2011-10-12 | メルク パテント ゲーエムベーハー | 複合サイトカイン−抗体複合体 |
| US8809504B2 (en) * | 2002-09-03 | 2014-08-19 | Vit Lauermann | Inhibitor which is deactivatable by a reagent produced by a target cell |
| EA200802289A1 (ru) | 2006-05-08 | 2009-04-28 | Филоджен Спа | Направляемые к мишени антителами цитокины для терапии |
| WO2008130382A2 (en) | 2006-10-31 | 2008-10-30 | East Carolina University | Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders |
| ES2536772T3 (es) | 2007-09-21 | 2015-05-28 | The Regents Of The University Of California | El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales |
| WO2009056268A1 (en) | 2007-10-30 | 2009-05-07 | Philogen S.P.A. | An antigen associated with rheumatoid arthritis |
| NZ592420A (en) | 2008-10-02 | 2012-12-21 | Emergent Product Dev Seattle | Cd86 antagonist multi-target binding proteins |
| US9249225B2 (en) * | 2010-05-26 | 2016-02-02 | Regents Of The University Of Minnesota | Single chain variable fragment anti-CD133 antibodies and uses thereof |
| WO2012045334A1 (en) | 2010-10-05 | 2012-04-12 | Synthon Bv | Biologically active il-10 fusion proteins |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| EP2736535B1 (en) | 2011-07-27 | 2018-10-17 | Philogen S.p.A. | Il-12 immunoconjugate |
| KR102277469B1 (ko) | 2011-12-12 | 2021-07-15 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 개선된 il-12 유전적 컨스트럭트 및 백신을 포함하는 조성물, 면역치료제 및 이를 이용하는 방법 |
| CN104245722A (zh) | 2012-02-29 | 2014-12-24 | Ambrx公司 | 白细胞介素-10多肽结合物和其用途 |
| CA2876285A1 (en) * | 2012-08-08 | 2014-02-13 | Roche Glycart Ag | Interleukin-10 fusion proteins and uses thereof |
| RU2612878C2 (ru) * | 2012-10-03 | 2017-03-13 | Филоджен С.П.А. | Антигены, ассоциированные с воспалительным заболеванием кишечника |
| KR20160043927A (ko) | 2013-03-14 | 2016-04-22 | 파카쉬 길 | 세포 표면 grp78에 결합하는 항체를 사용하는 암 치료 |
| AU2014257906A1 (en) | 2013-04-26 | 2015-12-10 | Philogen S.P.A. | IL4 conjugated to antibodies against extracellular matrix components |
| WO2015117930A1 (en) | 2014-02-06 | 2015-08-13 | F. Hoffmann-La Roche Ag | Interleukine 10 immunoconjugates |
| CN106659774A (zh) | 2014-05-16 | 2017-05-10 | 贝勒研究院 | 用于治疗自身免疫和炎性病症的方法和组合物 |
| CN104403004B (zh) | 2014-11-24 | 2017-10-13 | 苏州丁孚靶点生物技术有限公司 | 抗体‑干扰素异二聚体的制备和用途 |
| AU2015364396B2 (en) | 2014-12-19 | 2018-08-09 | Alkermes, Inc. | Single chain Fc fusion proteins |
| CA2986755A1 (en) | 2015-05-28 | 2016-12-01 | Armo Biosciences, Inc. | Pegylated interleukin-10 for use in treating cancer |
| KR101811050B1 (ko) | 2015-09-02 | 2017-12-21 | 경북대학교 산학협력단 | 항염증성 폴리펩티드와 페리틴 모노머 단편이 접합된 융합폴리펩티드 및 이를 유효성분으로 포함하는 염증성 질환 예방 및 치료용 약학적 조성물 |
| WO2017091611A1 (en) | 2015-11-23 | 2017-06-01 | Immungene, Inc | Enhanced cancer immunotherapy using antibody-interferon fusion molecules |
| UY37003A (es) | 2015-12-04 | 2017-06-30 | Novartis Ag | Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulacion |
| CN106349393B (zh) * | 2015-12-21 | 2020-10-30 | 合肥立方制药股份有限公司 | 一种增强抗体药物稳定性的结构 |
| CA3044556C (en) | 2016-04-12 | 2020-11-17 | Philogen S.P.A. | Combination therapy comprising an inflammatory immunocytokine and a chimeric antigen receptor (car)-t cell |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| WO2018156791A1 (en) | 2017-02-22 | 2018-08-30 | Aleta Biotherapeutics Inc. | Compositions and methods for tumor transduction |
| EP3625253A4 (en) * | 2017-05-16 | 2021-03-24 | Scalmibio, Inc. | ACTIVABLE ANTIBODIES AND THEIR METHODS OF USE |
| WO2019201866A1 (en) * | 2018-04-16 | 2019-10-24 | Swedish Orphan Biovitrum Ab (Publ) | Fusion protein |
| CA3100005A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| JP2022524018A (ja) | 2019-03-06 | 2022-04-27 | デカ バイオサイエンシーズ， インコーポレイテッド | Ｉｌ－１０バリアント分子ならびに炎症性疾患および腫瘍を処置する方法 |
| US20210214782A1 (en) | 2020-01-09 | 2021-07-15 | Deka Biosciences, Inc. | Method of using genetic markers, single nucleotide polymorphisms and/or indels to determine responsiveness to il-10 or il-10 derivative treatment |
| AU2021257439A1 (en) | 2020-04-13 | 2022-12-15 | University Health Network | Methods for treating cytokine release syndrome |
| CA3186753A1 (en) * | 2020-07-20 | 2022-01-27 | John Mumm | Dual cytokine fusion proteins comprising il-10 |
| CA3215528A1 (en) | 2021-05-11 | 2022-11-17 | Salvatore Albani | Chimeric antigen receptors and modified cells comprising the same |
| JP2024546938A (ja) | 2021-12-13 | 2024-12-26 | デカ バイオサイエンシーズ， インコーポレイテッド | マルチサブユニットサイトカインを含む二重サイトカイン融合タンパク質 |
| JP2024546999A (ja) | 2021-12-16 | 2024-12-26 | デカ バイオサイエンシーズ， インコーポレイテッド | Ｉｌ－１０を含む二重サイトカイン融合物およびがんを処置するための養子細胞療法または二重特異性ｔ細胞エンゲージャー |
| CN118900697A (zh) | 2022-02-22 | 2024-11-05 | 德卡生物科学公司 | 使用白细胞介素减轻双特异性t细胞接合器或嵌合抗原受体t细胞介导的细胞因子释放综合征的方法 |
-
2020
- 2020-12-02 CA CA3186753A patent/CA3186753A1/en active Pending
- 2020-12-02 EP EP20946024.5A patent/EP4181957A4/en active Pending
- 2020-12-02 IL IL300062A patent/IL300062A/en unknown
- 2020-12-02 JP JP2023504420A patent/JP2023534847A/ja active Pending
- 2020-12-02 MX MX2023000948A patent/MX2023000948A/es unknown
- 2020-12-02 BR BR112023001187A patent/BR112023001187A2/pt unknown
- 2020-12-02 CN CN202080105253.9A patent/CN116322785A/zh active Pending
- 2020-12-02 AU AU2020459746A patent/AU2020459746A1/en active Pending
- 2020-12-02 WO PCT/US2020/062907 patent/WO2022019945A1/en not_active Ceased
- 2020-12-02 KR KR1020237005848A patent/KR20230096959A/ko active Pending
-
2021
- 2021-03-11 US US17/199,239 patent/US11292822B2/en active Active
-
2022
- 2022-03-01 US US17/684,229 patent/US12268903B2/en active Active
- 2022-03-01 US US17/684,151 patent/US11613563B2/en active Active
- 2022-03-01 US US17/684,106 patent/US11572397B2/en active Active
- 2022-03-01 US US17/684,290 patent/US12263358B2/en active Active
- 2022-03-01 US US17/684,243 patent/US11629178B2/en active Active
- 2022-03-01 US US17/684,272 patent/US11618775B2/en active Active
- 2022-03-01 US US17/684,205 patent/US11608368B2/en active Active
-
2023
- 2023-11-03 US US18/501,584 patent/US12122814B2/en active Active
- 2023-11-03 US US18/501,884 patent/US12116392B2/en active Active
- 2023-11-03 US US18/501,571 patent/US12145007B2/en active Active
- 2023-11-03 US US18/501,561 patent/US12116389B2/en active Active
- 2023-11-03 US US18/501,914 patent/US12116393B2/en active Active
- 2023-11-03 US US18/501,741 patent/US12121755B2/en active Active
- 2023-11-03 US US18/501,581 patent/US12110317B2/en active Active
- 2023-11-03 US US18/501,762 patent/US12006346B2/en active Active
- 2023-11-03 US US18/501,856 patent/US12116391B2/en active Active
- 2023-11-03 US US18/501,850 patent/US12116390B2/en active Active
-
2024
- 2024-10-08 US US18/909,739 patent/US20250135241A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL300062A (en) | Dual fused cytokine proteins containing IL-10 | |
| US20210061925A1 (en) | Trispecific and/or trivalent binding proteins | |
| Kipriyanov et al. | Generation and production of engineered antibodies | |
| JP2025102819A5 (https=) | ||
| CN105777906B (zh) | 抗pd-l1全人抗体及其应用 | |
| Kontermann et al. | Bispecific antibodies | |
| Godar et al. | Therapeutic bispecific antibody formats: a patent applications review (1994-2017) | |
| JP2021520812A5 (https=) | ||
| JP2021098732A5 (https=) | ||
| JP2020536543A5 (https=) | ||
| IL313525A (en) | Dual cytokine fusion proteins containing multisubunit cytokines | |
| RU2451689C2 (ru) | Новые антипролиферативные антитела | |
| Teillaud | From whole monoclonal antibodies to single domain antibodies: think small | |
| JP2019519492A5 (https=) | ||
| JPWO2021155071A5 (https=) | ||
| Asano et al. | Domain order of a bispecific diabody dramatically enhances its antitumor activity beyond structural format conversion: the case of the hEx3 diabody | |
| JPWO2019200022A5 (https=) | ||
| JPWO2021011885A5 (https=) | ||
| JP2021517457A5 (https=) | ||
| US20240279362A1 (en) | Trispecific and/or trivalent binding proteins | |
| JPWO2020181235A5 (https=) | ||
| CN111886023A (zh) | 针对tim-3的抗体及其用途 | |
| JPWO2022019945A5 (https=) | ||
| Sugiyama et al. | A semi high-throughput method for screening small bispecific antibodies with high cytotoxicity | |
| JPWO2021104371A5 (https=) |